NEW YORK and GERMANTOWN, Md., Dec. 31, 2013 /PRNewswire/ -- Agilis Biotherapeutics, LLC, a synthetic biology-based company focused on rare genetic diseases, and Intrexon Corporation (NYSE: XON), a ...
The recent online publication of findings from the University of Southern California ataxia working group called Enigma served to fuel more interest in the simmering drug development space of ...
New Delhi [India], Dec 14 (ANI): With the government laying greater emphasis on protecting depositors’ money, the ASSOCHAM on Thursday urged the same to be clearly and unambiguously spelt out in the ...
FRDA is an inherited recessive disorder characterized by progressive neurological disability and heart abnormalities. The first symptoms usually develop in childhood, but the age of onset varies, ...
Minoryx Therapeutics, a phase 3 clinical stage biotech company, announces topline results from the phase 2 FRAMES clinical trial. The study evaluates leriglitazone, a novel, selective PPAR gamma ...
Agilis Biotherapeutics, LLC and Intrexon Corporation have announced an Exclusive Channel Collaboration (ECC) to develop DNA-based therapeutics for Friedreich’s ataxia (FRDA), a rare genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results